Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Mobile health monitoring in the management of long term conditions has potential benefits for patient care, especially when coupled with active adjustment of medication dosage. We report studies of patient-led self-titration of oral glucose lowering medication (OGLM) and insulin in type 2 diabetes, and dose adjustments (including dose increases) in oral chemotherapy for metastatic colorectal or breast cancer. Monitoring compliance was high in each case, and the feasibility of patients self-titrating OGLM or insulin following an agreed treatment plan was demonstrated. Chemotherapy dose increases supported by detailed toxicity profiles collected by phone have also been demonstrated.

Original publication




Journal article


Conf Proc IEEE Eng Med Biol Soc

Publication Date





1540 - 1543


Administration, Oral, Antimetabolites, Antineoplastic, Blood Glucose Self-Monitoring, Capecitabine, Deoxycytidine, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Therapy, Computer-Assisted, Female, Fluorouracil, Humans, Hypoglycemic Agents, Insulin, Neoplasms, Telemedicine, Treatment Outcome